Wu, FangSchweizer, ClaudeRudinskiy, NikitaTaylor, David M.Kazantsev, AlekseyLuthi-Carter, RuthFraering, Patrick C.2010-08-232010-08-232010-08-23201010.1096/fj.09-148031https://infoscience.epfl.ch/handle/20.500.14299/52368WOS:000279343600033Gamma-secretase is an intramembrane-cleaving protease responsible for the final proteolytic event in the production of the amyloid-beta peptides (Abeta) implicated in Alzheimer's disease (AD). Inhibition of gamma-secretase activity is thus an attractive therapeutic strategy to slow down the pathogenesis of AD. Drugs often target more than one biomolecule because of conserved 3-dimensional structures in prospective protein binding sites. We have capitalized on this phenomenon of nature to identify new gamma-secretase inhibitors. Here we show that 2-hydroxy naphthyl derivatives, a previously identified subclass of NAD(+) analog inhibitors of sirtuin 2 (SIRT2), are direct gamma-secretase inhibitors. Subsequent structure-activity relationship studies further showed that 2-hydroxy-1-naphthaldehyde is the minimal pharmacophore for gamma-secretase inhibition. In evaluating target protein determinants of inhibition, we identified a common GXG signature nucleotide-binding site (NBS) shared by the gamma-secretase subunit presenilin-1 C-terminal fragment (PS1-CTF), SIRT2, and Janus kinase 3 (JAK3). Because a detailed 3-dimensional structure of gamma-secretase is beyond our knowledge, we took advantage of the known crystal structure of human JAK3 to model the NBS of the PS1-CTF, which includes the catalytic residue D385. Our results suggest that the flexible PS1-CTF (381)LGLG(384) loop comprises a substrate-docking site capable of recognizing specifically different gamma-secretase substrates.Alzheimer's diseaseamyloid-beta peptidespresenilin-1off-target effectsubstrate-binding sitesAmyloid Precursor ProteinAlzheimers-DiseaseIdentificationDeacetylasesKinaseNicotinamideMechanismComplexDomainAlphatext::journal::journal article::research article